Rosuvastatin 20mg
Pro Research Analysisby 
Searched over 200M research papers for "rosuvastatin 20mg"
Rosuvastatin 20mg: Efficacy, Safety, and Metabolic Effects
Efficacy of Rosuvastatin 20mg in Lipid Management
Reduction in Triglycerides and LDL Cholesterol
Rosuvastatin 20mg has been shown to significantly reduce triglyceride (TG) levels and low-density lipoprotein cholesterol (LDL-C) in various patient populations. In Japanese patients with hypertriglyceridemia, rosuvastatin 20mg reduced TG levels by 32.3% compared to placebo, with no significant dose-related effect observed across different dosages 1. Additionally, in high-risk patients with hypercholesterolemia, rosuvastatin 20mg was more effective than atorvastatin 20mg in reducing LDL-C levels, achieving a 44.6% reduction compared to 42.7% with atorvastatin 3.
Achieving LDL-C Goals
In a study involving Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), rosuvastatin 20mg was effective in achieving the 2011 ESC/EAS LDL-C goal of <70 mg/dL in 68.3% of patients, although combination therapy with ezetimibe and rosuvastatin 10mg was superior 4. Similarly, in children with familial hypercholesterolemia, rosuvastatin 20mg reduced LDL-C by 50%, with 40% of participants achieving the target LDL-C level of <110 mg/dL 8.
Safety Profile and Adverse Effects
General Safety and Tolerability
Rosuvastatin 20mg is generally well tolerated, with a low incidence of adverse events. In the JUPITER trial, participants achieving very low LDL-C levels (<30 mg/dL) on rosuvastatin 20mg did not show increased risks of renal failure, cancer, memory impairment, or hemorrhagic stroke, although there were higher reports of diabetes, hematuria, and certain musculoskeletal and hepatobiliary disorders 6.
Metabolic Effects
Despite its lipid-lowering benefits, rosuvastatin 20mg has been associated with adverse metabolic effects. In hypercholesterolemic patients, rosuvastatin dose-dependently increased insulin levels and glycated hemoglobin, while decreasing adiponectin levels and insulin sensitivity 2. This suggests a potential risk for developing type 2 diabetes with high-dose rosuvastatin therapy.
Comparative Efficacy with Other Statins
Rosuvastatin vs. Atorvastatin
Comparative studies have shown that rosuvastatin 20mg is more effective than atorvastatin 20mg in reducing LDL-C and improving other lipid parameters. In the ARTMAP trial, rosuvastatin 10mg induced greater regression of coronary atherosclerosis compared to atorvastatin 20mg, highlighting its superior efficacy even at lower doses 9.
Rosuvastatin vs. Simvastatin
In patients with type 2 diabetes, rosuvastatin 20mg was less effective than simvastatin 20mg in improving endothelial function, as measured by flow-mediated dilation 5. This indicates that while rosuvastatin is potent in lipid reduction, its benefits on vascular function may vary compared to other statins.
Conclusion
Rosuvastatin 20mg is a highly effective statin for reducing triglycerides and LDL cholesterol, achieving lipid goals in various patient populations. However, its use is associated with certain metabolic risks, including decreased insulin sensitivity and increased glycemia. Comparative studies suggest that rosuvastatin may offer superior lipid-lowering benefits over atorvastatin but may be less effective than simvastatin in improving endothelial function. Overall, rosuvastatin 20mg remains a valuable option in lipid management, with a safety profile that warrants careful monitoring for metabolic side effects.
Sources and full results
Most relevant research papers on this topic
Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia.
Rosuvastatin effectively reduces triglyceride levels in hypertriglyceridemic Japanese patients, with no dose-related effect, but also improves other aspects of the atherogenic lipid profile.
RCTRosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients.
Rosuvastatin improves flow-mediated dilation in hypercholesterolemic patients, but reduces insulin sensitivity and increases glycemia by reducing adiponectin levels and increasing insulin levels.
RCT
Rigorous JournalComparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)
Rosuvastatin 10 mg is more effective and cost-effective than atorvastatin 20 mg in achieving low-density lipoprotein cholesterol goals in high-risk patients with hypercholesterolemia.
RCT
Large Human Trial
Very Rigorous Journal
Highly CitedA randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin.
The combination of rosuvastatin 10mg/ezetimibe 10mg is an effective alternative therapy for lowering LDL-C and reducing drug-related adverse events in Chinese patients with non-ST-elevation acute coronary syndrome.
RCTEarly vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes.
Rosuvastatin is less effective than simvastatin in improving endothelium-dependent vasodilation within one month in type 2 diabetic individuals without affecting insulin-resistance, adiponectin levels, and inflammation.
RCTSafety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER).
Achieving very low LDL-C levels with rosuvastatin 20 mg daily is generally well-tolerated but may increase the risk of certain adverse events, such as type 2 diabetes, hematuria, hepatobiliary disorders, and insomnia.
RCTLarge Human Trialpatient-oriented and epidemiological research Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes
Rosuvastatin 20 mg reduces HDL-apoA-I catabolic rate and restores normal HDL turnover in type 2 diabetes patients, potentially benefiting their health.
RCTEfficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.
Rosuvastatin 20 mg daily effectively reduced LDL-C levels in children with familial hypercholesterolemia, but only 40% achieved the consensus LDL-C target of 110 mg/dl.
RCTHighly CitedComparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
Rosuvastatin has a greater impact on reducing coronary atherosclerosis progression than atorvastatin in statin-naive patients, with both drugs showing significant regression.
RCTLarge Human TrialEffect of rosuvastatin on capillary filtration of albumin and blood pressure in rats with streptozotocin-induced diabetes.
Rosuvastatin prevents peripheral capillary filtration of albumin increase in diabetic rats and induces a decrease in blood pressure, but its beneficial effect on endothelial function does not appear to result from blood pressure reduction or lipid lowering effects.
RCT
Animal Study